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Purpose: Circulating free DNA (cfDNA) in plasma is promising to be a surrogate 
for tumor tissue DNA. However, not all epidermal growth factor receptor (EGFR) 
mutations in tumor tissue DNA has been detected in matched cfDNA, at least partly 
due to inefficient cfDNA extraction method. The purpose of this study was to estab-
lish an efficient plasma cfDNA extraction protocol. Materials and Methods: The 
yield of plasma cfDNA extracted by our modified phenol-chloroform (MPC) meth-
od from non-small-cell lung cancer (NSCLC) patients was compared with that by 
QIAamp MinElute Virus Spin kit (Qiagen kit) as control, using the Wilcoxon rank-
sum test. TaqMan quantitative polymerase chain  reaction (qPCR) assays were used 
to quantify the plasma cfDNA extracted. Both Mutant-enriched PCR (ME-PCR) 
coupled sequencing and DxS EGFR mutation test kit were used to evaluate the im-
pact of extraction method on EGFR mutation analysis. Results: MPC method ex-
tracted more plasma cfDNA than Qiagen kit method (p=0.011). The proportion of 
longer fragment (≥202 bp) in cfDNA extracted by MPC method was significantly 
higher than by Qiagen kit method (p=0.002). In the sequencing maps of ME-PCR 
products, a higher mutant peak was observed on plasma cfDNA extracted by MPC 
method than by Qiagen kit method. In DxS EGFR mutation test kit results, plasma 
cfDNA extracted by MPC method contained more tumor-origin DNA than by Qia-
gen kit method. Conclusion: An improved plasma cfDNA extraction method of 
MPC is provided, which will be beneficial for EGFR mutation analysis for patients 
with NSCLC.   
Key Words:    Circulating free DNA, DNA extraction, methodology, EGFR muta-
tion, non-small-cell lung cancer
INTRODUCTION
Non-small-cell lung cancer (NSCLC) accounts for about 80% of all patients with 
lung cancer,1 and most of NSCLC patients are first diagnosed at advanced stage. In 
the treatment of advanced NSCLC, chemotherapy is the mainstay but the response A Modified Extraction Method of Circulating Free DNA 
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Extraction of cfDNA 
The stored plasma sample was thawed at room temperature 
and centrifuged at 15,700 g for 15 min at 4°C to remove re-
sidual precipitated cellular components. Three methods 
were applied for the extraction of cfDNA, i.e. MPC meth-
od, traditional phenol-chloroform (PC) method, and com-
mercial QIAamp MinElute Virus Spin kit (Qiagen kit). 
For PC/MPC method, 1 mL of plasma was mixed with 
50 µL of 25% sodium lauryl sulfate (SDS) and 30 µL of 20 
mg/mL proteinase K (Qiagen, Hilden, Germany) and incu-
bated at 55°C for 16 h. After digestion, equal volume of 
water-saturated phenol was added into the sample and 
mixed. Then, the mixture was centrifuged at 16,000 g at 
room temperature for 15 min (PC method), or transferred 
into a Phase Lock Gel tube (MaXtract Low Density tube, 
Qiagen, Hilden, Germany) followed by centrifugation at 
16,000 g at room temperature for 5 min (MPC method). 
The supernatant was transferred into a new 2 mL eppendorf 
tube and mixed with equal volume of chloroform/isoamyl 
alcohol (24 : 1) mixture. The mixture was centrifuged at 
16,000 g for 15 min (PC method), or transferred into a 
Phase Lock Gel tube (MaXtract High Density tube, Qiagen, 
Hilden, Germany) followed by centrifugation at 16,000 g at 
room temperature for 5 min (MPC method). Sodium ace-
tate (3 mM) with 1 : 10 ratio of the supernatant and equal 
volume of isopropanol were added for DNA precipitation 
overnight at -20°C. DNA was dissolved in 50 µL of DNA 
hydration solution (Qiagen, Hilden, Germany) and stored at 
-20°C until use.
For Qiagen kit (Qiagen, Hilden, Germany) method, ex-
periment was performed according to manufacturer’s pro-
tocol, with the exception of increasing sample volume to 1 
mL and accordingly adding the reagent amount to 5-fold. 
Briefly, 1 mL of plasma was mixed with 62.5 µL of prote-
ase and 500 µL of buffer AL. After incubation at 56°C for 
15 min, 250 µL ethanol was added. The mixture was fil-
tered through the column and rinsed by AW1 and AW2 in 
order. DNA was dissolved in 50 µL of buffer AVE. 
Quantification and purity measurement of plasma 
cfDNA
TaqMan quantitative polymerase chain reaction (qPCR) as-
says targeting at DNA template of a single copy gene SER-
PINA1, whose copy number is confirmed to be relatively 
stable in solid tumors and has been used as internal refer-
ence gene indicating copy number of genomic DNA, were 
used to quantify the extracted cfDNA on ABI7900 real time 
rate is only 17-22%.2 Tyrosine kinase inhibitors (TKI) tar-
geting epidermal growth factor receptor (EGFR) have been 
used for the treatment of advanced NSCLC, and EGFR ac-
tivating mutation, which occurs in 30-50% of NSCLC pa-
tients in Asian and in 10% in Caucasian, has been proved to 
be the critical factor for TKI efficacy.3-5 The response rate is 
around 75% for NSCLC patients with tumor EGFR activat-
ing mutation versus less than 10% for those with wild-type 
EGFR.6 Therefore, EGFR mutation analysis is important for 
decision of TKI therapy for NSCLC patients. 
Tumor tissue is the most optimal sample type for genomic 
DNA extraction for EGFR mutation analysis. However, tu-
mor tissue samples are not always available from advanced 
NSCLC patients in clinical practice. Circulating free DNA 
(cfDNA) in plasma has thus been used as a surrogate for tu-
mor tissue DNA for EGFR mutation analysis, and results 
from preliminary studies seemed promising.7-9 However, not 
all EGFR mutations in tumor tissue DNA has been detected 
in matched cfDNA,7-9 at least partly due to inefficient cfDNA 
extraction method. In the present study, we provided an im-
proved plasma cfDNA extraction method, i.e. modified phe-
nol-chloroform (MPC) method. Since QIAamp MinElute Vi-
rus Spin kit, in comparison with several other commercially 
available kits, has been reported to yield the highest amount 
of cfDNA,10 we compared our MPC method to Qiagen kit 
method on cfDNA extraction yield and the impact of differ-
ent extraction method on EGFR mutation analysis. 
MATERIALS AND METHODS
　　　
Subjects and samples
A total of 25 patients with advanced lung adenocarcinoma 
were recruited from No.3 People’s Hospital, School of Medi-
cine, Shanghai Jiaotong University, China between March 
and September 2009. Written informed consent was ob-
tained from each subject. This study was approved by the 
ethics review committee of the Institutional Review Board 
of the hospital.
Five mL of peripheral whole blood were collected from 
each subject, which was put into an EDTA-Vacutainer tube 
(BD, Plymouth, UK) to separate plasma. All samples were 
processed at room temperature within 2 h from the time of 
blood drawing. Plasma was separated from the cellular frac-
tion by centrifugation at 2,500 g for 10 min at 4°C. After cen-
trifugation, the supernatant was transferred to eppendorf tube 
and stored immediately at -80°C until cfDNA extraction. Haihua Yuan, et al.
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for 30 s, 56°C for 60 s, and 72°C for 60 s. A 5 µL aliquot of 
1st PCR product was digested for 4 h at 37°C in a 20 µL re-
action volume containing 5 units of Mse I enzyme (New 
England Biolabs, Beverly, MA, USA), to digest the TTAA 
sequence within the deletion target region of wild-type 
DNA. For the 2nd PCR, forward and reverse primers were 
5’-ACT GTA AAA CGA CGG CCA GTA TCC CAG 
AAG GTG AGA AAG ATA AAA TTC-3’ and 5’-ACC 
AGG AAA CAG CTA TGA CCA CAC AGC AAA GCA 
GAA ACT CAC ATC GAG-3’, respectively. The 2nd PCR 
was performed with 25 µL reaction volume containing 5 
µL of the digested product above and the same concentra-
tions of primers and AmpliTaq Gold PCR Master Mix as 
the 1st PCR reaction, with the cycling condition of 95°C for 
10 min followed by 40 cycles of 94°C for 30 s, 60°C for 30 
s, 72°C for 40 s, ended with 72°C for 10 min. The 2nd PCR 
product was applied for Sanger sequencing according to the 
standard protocol in the manual of ABI prism 3730XL 
DNA analyzer (Applied Biosystems, Foster City, CA, 
USA) using common M13R primer (sequence: ACC AGG 
AAA CAG CTA TGA CC). Sequencing results were ana-
lyzed using the SeqScape software v2.5 (Applied Biosys-
tems, Foster City, CA, USA).
A DxS EGFR mutation test kit (DxS Ltd, Manchester, 
UK), which combines amplification refractory mutation 
system and Scorpion technologies, was also used to detect 
known EGFR mutations in real-time PCR as described pre-
viously.11,12 All reactions were performed in 25 uL volumes 
including 5 uLof template DNA, 16 uL of reaction buffer 
mix, 0.6 uL of Taq polymerase and 3.4 uL water. Real-time 
PCR was carried out by using MX3005P real-time PCR 
machine (Stratagene, La Jolla, CA, USA) under the follow-
ing conditions: initial denaturation at 95°C for 10 min, 45 
cycles of 95°C 30 s, 61°C 60 s with fluorescence FAM 
reading at the end of each cycle. Data analysis was per-
formed with MxPro v4.10 (Stratagene, La Jolla, CA, USA). 
The Cycle threshold (Ct) represents the threshold at which 
the signal is detected above background fluorescence. Sam-
ple ΔCt values are calculated as the difference between the 
mutation Ct and control Ct. If the sample’s ΔCt is lower 
than the cut-off ΔCt value, it is judged as positive for a mu-
tation detected by this assay. The cut-off ΔCt value is 12 for 
deletion in exon 19 of EGFR. The bigger the ΔCt is, the 
less mutation the sample contains.
Statistical analysis 
The nonparametric comparison of median cfDNA yield be-
PCR machine (Applied Biosystems, Foster City, CA, 
USA). Forward primers for 77 bp, 123 bp and 202 bp PCR 
products were 5’-TAC TCA AGG GAA AAT TGT GGA 
TTT-3’, 5’-ACA CCG AAG AGG CCA AGA A-3’ and 5’-
GGC CTG AAG CTA GTG GAT AAG TT-3’, respectively. 
Common reverse primer was 5’-AGA AGA TGT AAT TCA 
CCA GAG CAA A-3’. The probe sequence was 5’-FAM-
TGT GTC TCT GTC AAG CTC CTT GAC-3’BHQ1. The 
15 µL reaction mixture contained 7.5 µL platinum qPCR 
superMix-UDG (Invitrogen, Paisley, UK), 4.3 µL of pure 
water, 0.6 µL of 0.1 µM/L primer, 0.6 µL of 0.2 µM/L 
probe, and 2 µL of cfDNA. PCR was performed at 95°C 
for 10 min, followed by 40 cycles of 94°C for 30 s, 60°C for 
60 s and 72°C for 15 s. The results were analyzed with soft-
ware SDS 2.3. Each sample was tested in three replicates 
and their average was used in the statistical analysis. Quan-
tity of cfDNA was expressed in copies/mL.
Purity of the plasma cfDNA extracted by PC, MPC and 
Qiagen kit method was spectrophotometrically evaluated 
using OD (260 nm/280 nm) value determined with the 
NanoDrop spectrometer ND-1000 (NanoDrop, Rockland, 
Delaware, USA).
EGFR mutation analysis 
For all the 25 patients recruited in the present study, tumor 
tissue DNA has previously been examined for mutation in 
exon 19 of the EGFR gene by PCR-based sequencing, and 
only one small fragmental deletion, 2235-2249delGGAAT-
TAAGAGAAGC, was identified in one patient (unpublished 
data). Thus, EGFR mutation analysis was performed on 
plasma cfDNA from this patient, by Mutant-enriched PCR 
(ME-PCR) coupled sequencing and DxS EGFR mutation 
test kit. Plasma cfDNA extracted by MPC and Qiagen kit 
method was used for EGFR mutation analysis.
The principle of the ME-PCR coupled sequencing meth-
od was that a wild-type specific enzyme digestion step was 
inserted before the second PCR of the nest-PCR process, 
which enriched mutant-type PCR products for subsequent 
sequencing analysis.8 For the 1st step PCR, forward and re-
verse primers were 5’-ATC CCA GAA GGT GAG AAA 
GAT AAA ATT C-3’ and 5’-CCT GAG GTT CAG AGC 
CAT GGA-3’, respectively. PCR reaction mixture con-
tained 25 µL of AmpliTaq Gold PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA), 1 µL of 2.5 M primer 
(Invitrogen, Paisley, UK), 1.5 µL of 20 mg/mL BSA, 1.5 
µL of pure water and 20 µL of cfDNA. PCR was per-
formed at 95°C for 10 min followed by 35 cycles of 94°C A Modified Extraction Method of Circulating Free DNA 
Yonsei Med J   http://www.eymj.org   Volume 53   Number 1   January 2012 135
In contrast to the moderate impurities of plasma cfDNA 
extracted by PC method, the MPC and Qiagen kit methods 
extracted similarly better purity of cfDNA, as determined 
by spectrophotometric measurements (data not shown).
Comparison of fragment distribution between cfDNA 
extracted by MPC and Qiagen kit method
The percentage of cfDNA size of 77-122 bp, 123-201 bp and 
≥202 bp extracted by MPC method were 8.2%, 37.6% and 
54.2%, respectively, whereas 15.4%, 52.4% and 32.2%, re-
spectively, extracted by Qiagen kit (Fig. 2). The proportion 
of longer fragment (≥202 bp) in cfDNA extracted by MPC 
method (54.2%) was significantly higher than by Qiagen 
kit method (32.2%, p=0.002) (Fig. 2).
Impact of extraction method on EGFR mutation 
analysis 
ME-PCR coupled sequencing method and the DxS EGFR 
mutation test kit were used for EGFR mutation analysis of 
tween groups were evaluated using the Wilcoxon rank-sum 
test. Exact chi-square test was used to evaluate the differ-
ence in fragment distribution of cfDNA between MPC meth-
od and Qiagen kit method. All tests were two-sided and a p 
value of less than 0.05 was considered significant. Statistical 
analyses were conducted using SPSS 13.0 software (SPSS, 
Inc., Chicago, IL, USA). 
RESULTS
 
Comparison of yield and purity of the plasma cfDNA 
extracted by MPC, PC and Qiagen kit method 
Plasma cfDNA was extracted from all 25 patients by MPC, 
PC and Qiagen kit methods. As expected, MPC method ex-
tracted more cfDNA than PC method (p=0.005). When com-
pared with the Qiagen kit method, significantly elevated 
cfDNA yield was also observed by MPC method (p=0.011) 
(Fig. 1).
Fig. 1. Comparison of cfDNA yield extracted by modified phenol-
chloroform (MPC) method and QIAamp MinElute Virus Spin kit 
(Qiagen kit). 
Fig. 3. Sequencing maps of known EGFR deletion in exon 19 of plasma cfDNA. cfDNA was extracted by modified phenol-chloroform 
(MPC) method (A) and QIAamp MinElute Virus Spin kit (Qiagen kit) (B). In (A), the height of mutant peak is similar to that of wild-type peak, 
while the height of mutant peak in (B) is much lower than that of wild-type peak. EGFR, epidermal growth factor receptor.
Fig. 2. Comparison of fragment distribution of plasma cfDNA ex-
tracted by modified phenol-chloroform (MPC) method and 
QIAamp MinElute Virus Spin kit (Qiagen kit).
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tracted by PC method which is consistent with previous data 
by Müller, et al.,19 the purity of cfDNA extracted by MPC 
method was better, similar to that by Qiagen kit method.
By comparing several commercially available cfDNA 
extraction kits, Board, et al.10 reported that QIAampVirus 
Spin kit was the one yielding the highest amount of plas-
ma cfDNA from patients with small cell lung cancer 
(SCLC).Therefore, we chose QIAamp Virus Spin kit as a 
reference method to test the performance of the MPC meth-
od for cfDNA extraction yield in plasma. Our data showed 
that MPC method extracted more plasma cfDNA than Qia-
gen kit method, and that cfDNA extracted by MPC method 
contained higher percentage of longer fragment (≥202 bp). 
cfDNA extracted by MPC method was more intact than by 
Qiagen kit method. Furthermore, we compared the impact of 
different extraction method of MPC or Qiagen kit on EGFR 
mutation analysis. Results from both sequencing maps of 
ME-PCR products and DxS EGFR mutation test suggested 
that MPC method is superior to Qiagen kit on plasma cfD-
NA extraction for analysis of mutant EGFR. It has been 
suggested that tumor-specific cfDNA is enriched in the 
DNA portion containing shorter fragments, while serum 
cfDNA isolated by the Qiagen kit method has been demon-
strated to be enriched in high-molecular-weight DNA.19,20 
Thus, the enhanced sensitivity of detection of mutant EGFR 
by MPC method versus Qiagen kit method may partly be 
attributable to more tumor-specific cfDNA extracted by 
MPC method. Considering that small DNA molecules are 
partially lost by the Qiagen kit extraction method,19,20 a new 
kit from Qiagen for the extraction of cfDNA, QIAmp Cir-
culating Nucleic Acid Kit, has most recently been devel-
oped, which improves the extraction of small DNA frag-
ments. Further studies are needed to compare our MPC 
method to the new Qiagen kit method in cfDNA extraction 
yield, as well as fragment distribution and the impact on 
EGFR mutation analysis.
In summary, we described an improved cfDNA extrac-
tion method of MPC which will be beneficial for EGFR 
mutation analysis for patients with NSCLC. Additional 
studies with sufficient number of patients are needed to val-
idate the efficiency and reliability of the MPC method for 
cfDNA extraction.
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